• Targos projectmanagement Team and Targos building

  • Targos Lab Team

  • Targos Logistics Team

  • Targos Advance Team

  • Targos Study Office Team

  • Targos employees and Targos building

  • Expert Training by Targos

  • Expert Training - microscope room

Targos - A Leader in Biomarker Services for more than 10 years

Targos GmbH building and staff 2015

Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry.

The company has supported more than 400 international clinical trials since 2005, which have led to the successful approval of several targeted therapies and IVDs for our customers.

The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market.

Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). Since 2014 Targos Molecular Pathology GmbH is accredited by the College of American Pathologists and the US-CLIA program.

Targos News


We offer PD-L1/PD-1 Immuno-Oncology Training and Testing

PD-L1 NSCLC microscope slide

Targos offers PD-L1 training in many indications. In addition, we also provide PD-L1 testing services within clinical trials utilizing currently commercially available PD-L1 IVD assays (SP142, SP263, 22C3, 28-8) validated in a fully CAP/CLIA compliant environment.

VENTANA PD-L1 (SP142) Assay – Solid Tumors, including NSCLC, and Urothelial Bladder Carcinoma
VENTANA PD-L1 (SP263) Assay – Solid Tumors, including NSCLC
Agilent PD-L1 IHC 22C3 pharmDx – Solid Tumors, including NSCLC
Agilent PD-L1 IHC 28-8 pharmDx – NSCLC and Melanoma. Urothelial bladder carcinoma tests will be available soon!

We also offer fully validated laboratory developed tests using anti-PD-L1 antibody clones 28-8 and E1L3N (to be available soon); and are currently working on diverse IHC multiplex assays and digital image analysis algorithms.
In addition, we also offer “off-label” application of any reagents in a “research-use” only environment as per our customer specific requirements. Please note that standard evaluation algorithms or cut-offs may not be applicable in other indications and must be technically validated prior to application.
For more information regarding PD-L1 testing or other assays, please contact us at info@targos-gmbh.com